U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499908) titled 'Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013' on March 24.
Brief Summary: This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Healthy Adult
Intervention:
DRUG: CIT-013 high dose
CIT-013
DRUG: Placebo
placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Citryll BV
Disclaimer: Curated by HT Syndication....